Angiotensin II Type 1 Receptor Blockers
-
Subject Areas on Research
-
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial.
-
Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
-
Albuminuria in chronic heart failure: prevalence and prognostic importance.
-
Angiotensin Analogs with Divergent Bias Stabilize Distinct Receptor Conformations.
-
Angiotensin II acts through the angiotensin 1a receptor to upregulate pendrin.
-
Angiotensin II and hypertonicity modulate proximal tubular aquaporin 1 expression.
-
Angiotensin II plays a role in acute murine experimental autoimmune cystitis.
-
Angiotensin II promotes development of the renal microcirculation through AT1 receptors.
-
Angiotensin receptor signaling and prostate tumor growth in mice.
-
Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-/- mice.
-
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: Future research needs prioritization.
-
Association Between Change in Central Nocturnal Blood Pressure and Urine Albumin-Creatinine Ratio by a Valsartan/Amlodipine Combination: A CPET Study.
-
Association between patient beliefs and medication adherence following hospitalization for acute coronary syndrome.
-
Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program.
-
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
-
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
-
Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes.
-
Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF).
-
Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.
-
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM.
-
Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
-
Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme.
-
Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury.
-
Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Activated intrarenal renin-angiotensin system is correlated with high blood pressure in humans.
-
Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.
-
Coronary constriction to angiotensin II is enhanced by endothelial superoxide production in sheep programmed by dexamethasone.
-
Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials.
-
DIRECT new treatments for diabetic retinopathy.
-
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program.
-
Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction.
-
Distinctive Activation Mechanism for Angiotensin Receptor Revealed by a Synthetic Nanobody.
-
Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis.
-
Dual renin-angiotensin system blockade in heart failure.
-
Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome.
-
Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
-
Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure.
-
Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance.
-
Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits.
-
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme.
-
FPIN's clinical inquiries. Angiotensin blockade in patients with diabetic nephropathy.
-
Heart failure drug treatment.
-
Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure).
-
Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
-
Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
-
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction).
-
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
-
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure.
-
Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF.
-
Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.
-
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
-
International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
-
International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
-
Is home blood pressure variability itself an interventional target beyond lowering mean home blood pressure during anti-hypertensive treatment?
-
Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes.
-
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
-
Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
-
Nebivolol in older adults with heart failure: reduced rates for seniors?
-
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
-
Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery.
-
Outpatient management of heart failure in the United States, 2006-2008.
-
Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
-
Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States.
-
Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial.
-
Predictors of Rapid Aortic Root Dilation and Referral for Aortic Surgery in Marfan Syndrome.
-
Predictors of survival after cardiac arrest in outpatient hemodialysis clinics.
-
Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme.
-
Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.
-
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
-
Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
-
Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program.
-
Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program.
-
Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both.
-
Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.
-
Reactive oxygen species blockade and action of insulin on expression of angiotensinogen gene in proximal tubular cells.
-
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
-
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
-
Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.
-
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
-
Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
-
Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan.
-
Safety of symptom-limited cardiopulmonary exercise testing in patients with chronic heart failure due to severe left ventricular systolic dysfunction.
-
Strategies to attenuate pathological remodeling in heart failure.
-
Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension.
-
Systemic management of diabetic retinopathy.
-
Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathic pain.
-
The CHARM programme.
-
The cardiovascular continuum and renin-angiotensin-aldosterone system blockade.
-
The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients.
-
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
-
The effects of cytotoxic therapy in progressive IgA nephropathy.
-
The renin-angiotensin system and diabetic nephropathy.
-
The role of angiotensin II in stress urinary incontinence: A rat model.
-
The role of heart failure pharmacotherapy after left ventricular assist device support.
-
Therapeutic implications of high-dose angiotensin receptor blocker monotherapy in mild-to-moderate hypertensive patients.
-
Transactivation of the epidermal growth factor receptor by angiotensin II in glomerular podocytes.
-
Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the get with the guidelines quality-improvement program.
-
Use of guideline-recommended therapies for heart failure in the Medicare population.
-
Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome.
-
Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial.
-
Weekend/holiday versus weekday hospital discharge and guideline adherence (from the American Heart Association's Get with the Guidelines--Coronary Artery Disease database).
-
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
-
Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
-
β-Arrestin mediates the Frank-Starling mechanism of cardiac contractility.
-
β-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury.
-
Keywords of People
-
Alexander, John Hunter Peel,
Professor of Medicine,
Medicine, Cardiology
-
Granger, Christopher Bull,
Professor of Medicine,
School of Nursing
-
O'Connor, Christopher Michael,
Adjunct Professor in the Department of Medicine,
Medicine, Clinical Pharmacology